Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2101 to 2150 of 3030 results for all

  1. Early value assessment interim statement (PMG39)

    This interim statement outlines early value assessments, a new evidence-based approach designed to improve the care of people and effective use of NHS resources through quicker access to promising health technologies that address national unmet need

  2. Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment (HTG759)

    Late stage assessment (LSA) guidance on bed frames for adults in acute medical or surgical hospital wards.

  3. Sleepio to treat insomnia and insomnia symptoms (HTG624)

    Evidence-based recommendations on Sleepio to treat insomnia and insomnia symptoms.

  4. PleuraFlow Active Clearance Technology for maintaining chest tube patency (MIB125)

    NICE has developed a medtech innovation briefing (MIB) on PleuraFlow Active Clearance Technology for maintaining chest tube patency .

  5. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (TA243)

    Evidence-based recommendations on rituximab for the first-line treatment of stage III–IV follicular lymphoma.

  6. Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma (TA319)

    Evidence-based recommendations on ipilimumab (Yervoy) for previously untreated advanced (unresectable or metastatic) melanoma in adults.

  7. Archimedes for biopsy of suspected lung cancer (MIB211)

    NICE has developed a medtech innovation briefing (MIB) on Archimedes for biopsy of suspected lung cancer .

  8. International collaboration

    International collaboration with NICE

  9. Optical coherence tomography to guide percutaneous coronary intervention (HTG332)

    Evidence-based recommendations on optical coherence tomography to guide percutaneous coronary intervention. This involves using near-infrared light to produce high-resolution images of blood vessel walls.

  10. Laparoscopic helium plasma coagulation for the treatment of endometriosis (HTG112)

    Evidence-based recommendations on laparoscopic helium plasma coagulation for the treatment of endometriosis. This involves a minimally invasive procedure used to vaporise endometrial deposits.

  11. Extracorporeal shockwave therapy for refractory greater trochanteric pain syndrome (HTG248)

    Evidence-based recommendations on extracorporeal shockwave therapy for refractory greater trochanteric pain syndrome. This involves using a machine to deliver sound waves to the painful area to stimulate healing.

  12. Sinus tarsi implant insertion for mobile flatfoot (HTG196)

    Evidence-based recommendations on sinus tarsi implant insertion for mobile flatfoot. This involves surgery to insert an implant just above the heel bone, with the aim of correcting the condition and improving symptoms.

  13. Microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma (HTG470)

    Evidence-based recommendations on microinvasive subconjunctival insertion of a trans-scleral gelatin stent for primary open-angle glaucoma in adults. This involves putting a tiny gelatin tube (stent) under the skin at the base of the eye to create a new drainage channel for excess fluid.

  14. Photodynamic therapy for localised inoperable endobronchial cancer (HTG85)

    Evidence-based recommendations on photodynamic therapy (PDT) for localised inoperable endobronchial cancer (non-small-cell lung cancer). This involves injecting a photosensitising agent into the body that is activated by laser light to destroy the cancerous tissue.

  15. Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]

    In development Reference number: GID-TA11220 Expected publication date: TBC

  16. Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)

    Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.

  17. Pirfenidone for treating idiopathic pulmonary fibrosis (TA504)

    Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis in adults.

  18. Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)

    Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making

  19. Implantation of a left ventricular assist device for destination therapy in people ineligible for heart transplantation (HTG369)

    Evidence-based recommendations on implantation of a left ventricular assist device for destination therapy in people ineligible for heart transplantation.

  20. Cabotegravir for preventing HIV-1 in adults and young people (TA1106)

    Evidence-based recommendations on cabotegravir (Apretude) for preventing HIV-1 in adults and young people.

  21. Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over (TA1147)

    Evidence-based recommendations on vorasidenib (Voranigo) for treating grade 2 astrocytoma or oligodendroglioma in people 12 years and over.

  22. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  23. Indicator advisory committee members

    Read biographies for all members of NICE's indicator advisory committee.

  24. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at moderately increased risk

    How important is this to me? Very important Important Not important Not at all important Taking a tablet every day for 5 years The...

  25. Familial breast cancer. Patient decision aid on taking tamoxifen to reduce the chance of developing breast cancer for premenopausal women at high risk

    How important is this to me? Very important Important Not important Not at all important Taking a tablet every day for 5 years The...

  26. AmnioSense for unexplained vaginal wetness in pregnancy (MIB198)

    NICE has developed a medtech innovation briefing (MIB) on AmnioSense for unexplained vaginal wetness in pregnancy .

  27. Optowire for measuring fractional flow reserve (MIB199)

    NICE has developed a medtech innovation briefing (MIB) on Optowire for measuring fractional flow reserve .

  28. LQD Spray for treating acute and chronic wounds (MIB202)

    NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .

  29. The NGAL Test for early diagnosis of acute kidney injury (MIB3)

    NICE has developed a medtech innovation briefing (MIB) on the NGAL Test for early diagnosis of acute kidney injury .

  30. Contrast-enhanced spectral mammography for breast cancer (MIB304)

    NICE has developed a medtech innovation briefing (MIB) on contrast-enhanced spectral mammography for breast cancer .

  31. Stretta System for gastro-oesophageal reflux disease (MIB74)

    NICE has developed a medtech innovation briefing (MIB) on the Stretta System for gastro-oesophageal reflux disease

  32. CentriMag for heart failure (MIB92)

    NICE has developed a medtech innovation briefing (MIB) on CentriMag for heart failure .

  33. CareLink network service for remote monitoring of people with cardiac devices (MIB64)

    NICE has developed a medtech innovation briefing (MIB) on the CareLink network service for remote monitoring of people with cardiac devices

  34. The OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic joint revision (MIB13)

    NICE has developed a Medtech Innovation Briefing (MIB) on the OSCAR 3 ultrasonic arthroplasty revision instrument for removing bone cement during prosthetic

  35. Active B12 assay for diagnosing vitamin B12 deficiency (MIB40)

    NICE has developed a medtech innovation briefing (MIB) on the Active-B12 assay for diagnosing vitamin B12 deficiency

  36. Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia (TA450)

    Evidence-based recommendations on blinatumomab (Blincyto) for treating Philadelphia-chromosome-negative precursor B-cell acute lymphoblastic leukaemia in adults.

  37. Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)

    Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults.

  38. Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)

    Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer in adults.

  39. Bortezomib and thalidomide for the first‑line treatment of multiple myeloma (TA228)

    Evidence-based recommendations on bortezomib (Velcade) and thalidomide (Thalidomide Celgene) for treating multiple myeloma in adults.

  40. Evinacumab for treating homozygous familial hypercholesterolaemia in people 12 years and over (TA1002)

    Evidence-based recommendations on evinacumab (Evkeeza) for treating homozygous familial hypercholesterolaemia in people 12 years and over.

  41. Apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer (TA740)

    Evidence-based recommendations on apalutamide with androgen deprivation therapy for treating high-risk hormone-relapsed non-metastatic prostate cancer in adults.

  42. Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1023)

    Evidence-based recommendations on elranatamab (Elrexfio) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.

  43. Elacestrant for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment (TA1036)

    Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation after endocrine treatment in adults.

  44. Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is unsuitable (TA1170)

    Evidence-based recommendations on daratumumab (Darzalex) with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma in adults when a stem cell transplant is unsuitable.

  45. Transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation (HTG771)

    Evidence-based recommendations on transcatheter tricuspid valve implantation for symptomatic severe tricuspid regurgitation. This involves putting an artificial valve inside the existing faulty valve.

  46. Low-energy contact X-ray brachytherapy for rectal cancer (HTG763)

    Evidence-based recommendations on low-energy contact X-ray brachytherapy for rectal cancer. This involves inserting an X-ray tube through the anus into the rectum. The tube is placed in contact with the tumour and releases a low dose of X-ray radiation (brachytherapy) directly to it.

  47. Autologous blood injection for tendinopathy (HTG299)

    Evidence-based recommendations on autologous blood injection for tendinopathy. This involves supplying the tendon with growth factors that start the healing process.

  48. Normothermic extracorporeal preservation of hearts for transplantation following donation after brainstem death (HTG404)

    Evidence-based recommendations on normothermic extracorporeal preservation of hearts for transplant after brainstem death. This technique is used to store a donor heart for longer before being transplanted.

  49. Endobronchial nerve ablation for chronic obstructive pulmonary disease (HTG604)

    Evidence-based recommendations endobronchial nerve ablation for chronic obstructive pulmonary disease. This involves destroying (ablating) the nerves on the outside of the airway (endobronchial nerves) to improve breathing.

  50. Radiofrequency valvotomy for pulmonary atresia (HTG57)

    Evidence-based recommendations on radiofrequency valvotomy for pulmonary atresia. This involves making a hole in the blocked valve, and inserting and inflating a small balloon to widen it.